Baird analyst Eric Coldwell maintains Icon (NASDAQ:ICLR) with a Outperform and raises the price target from $265 to $285.
Abeona Therapeutics Provides Regulatory Update On Pz-cel; CRL Did Not Identify Deficiencies Related To Clinical Efficacy Or Clinical Safety Data In BLA, And No New Clinical Studies Requested By FDA To Support Approval
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies
